Patients
For the latest information on our multi-center phase I/II U.S. clinical trials evaluating T-cell therapies for the treatment of cancer, please visit
WHAT ARE CLINICAL TRIALS?
Before a new therapy can be made available to the general public, a clinical trial must be carefully designed to examine the safety and clinical benefit of an investigational therapy. Clinical trials help address important questions, such as how a new therapy acts in the body, how it affects certain diseases or conditions, and if it is safe for wider use. Clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by equivalent regulatory agencies in other countries.
Finding a cure, together.
EXPANDED ACCESS POLICY
Eureka Therapeutics is committed to developing next-generation T-cell therapies for cancer patients who have serious and life-threatening diseases or conditions.
Our Expanded Access Policy (EAP) refers to the use of an investigational cell therapy outside of a clinical trial. Sometimes called “compassionate use”, expanded access is a potential pathway for a patient to gain access to investigational therapies in certain rare circumstances in which a person has no other available therapies or is not eligible to participate in a current Eureka clinical trial. At Eureka, we recognize and understand the need for an expanded access policy for patients who have serious or immediately life-threatening disease and have limited available treatment options.
The decision to establish an EAP is dependent on several key factors consistent with the US Food and Drug Administration (FDA) and other regulatory agencies’ guidelines. These include, but are not limited, to the following:
The patient or patients to be treated have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition;
The potential patient benefit justifies the potential risks of using the treatment and those potential risks are not unreasonable in the context of the disease or condition to be treated; and
Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the expanded access use or otherwise compromise the potential development of the expanded access use.
Eureka believes that participation in one of our clinical trials is the best way to access our investigational cell therapies. We encourage patients to speak with their physicians regarding participating in clinical trials. In rare cases where patients with serious diseases are unable to participate in clinical trials and have exhausted all available options, Eureka may consider providing our investigational therapies outside of a clinical trial. As a general policy, Eureka will not provide our investigational therapies until sufficient preliminary safety and efficacy information has been obtained in our clinical trials, typically following Phase 2 investigation.
If you are a patient who is interested in accessing our investigational cell therapies, please speak with your physician. You may also learn more about ongoing clinical trials by going to www.clinicaltrials.gov and searching for Eureka Therapeutics.
If you are a physician who is interested in learning more about our investigational cell therapies, or participating in our clinical trials, please submit a request to clinicaltrials@eurekainc.com.
